Friday, 16 October 2026European Markets

AUGROS COSMETICS Stock Tumbles 12% Amid Bearish Momentum

Loading stream...

(vianews) - shares of augros cosmetics (augr.pa) fell 12.82% at 16:31 est wednesday afternoon to eur6.80 following three consecutive sessions of losses. yet broader market indices like the cac 40 (cac40) rose by 0.06% on wednesday to eur7,377.83 suggesting an optimistic trend for wednesday trading sessions.

about augros cosmetics

augros cosmetic packaging sa is a french company offering tailored packaging solutions for the perfume, cosmetic, and spirit industries. specializing in glass, plastic and aluminum packaging materials as well as decoration services tailored specifically for each client, augros operates out of alencon as part of famille bourgine.

technical analysis

augros cosmetics, a cosmetics manufacturer and distributor, experienced a drastic drop in trading volume today compared to its average volume of 64 shares traded every day. investors do not appear interested in trading the stock during this time. augros cosmetics has experienced mixed performances over the last several weeks and months when it comes to volatility. within the last week, its intraday variation average was positive 16.42% which indicates some level of price fluctuations; however, for both months and quarters prior, its average volatility has been negative 0.20% and positive 8.08%, suggesting that its price has been relatively stable while experiencing some price changes over this time frame. noting augros cosmetics' highest average weekly, monthly, and quarterly volatility figures of 16.42% for last week; 8.07 %; and 8% respectively suggests significant price changes could occur in the near future; this should alert investors that it's prudent to closely track this stock's performance as well as potential price variations in order to stay prepared for unexpected developments in its price.

equity analysis

augros cosmetics currently generates an earnings per share value of eur0.43 over its trailing twelve month period, signifying that their earnings per share amount to that amount for investors. a pe ratio of 15.81 indicates that investors are paying eur15.81 for every euro of annual earnings generated. this number stands out compared to similar companies operating within its industry. when investing in augros cosmetics, it is crucial that the profitability and valuation are evaluated in relation to overall market and industry trends. a handy way of doing this would be comparing its pe ratio against that of its competitors to determine if it is over or undervalued. furthermore, investors should take into account additional factors like growth prospects, financial health status and management team when making investment decisions.

more news about augros cosmetics (augr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com